InvestorsHub Logo
Followers 27
Posts 3416
Boards Moderated 0
Alias Born 07/17/2006

Re: mojojojo post# 106918

Tuesday, 01/08/2013 1:22:47 PM

Tuesday, January 08, 2013 1:22:47 PM

Post# of 346475
Right on brother mojojojo! Or is that sister mojojojo? If the front line NSCLC trial MOS is 50-75% better than the SOC, and the same holds true from the Pancreatic cancer trial, I don't see any way this stock stays below $5. As we all know these two trials must be nearing positive MOS announcements. At this point it seems that the only question is how much Bavi MOS improves on the SOC in these deadly diseases.

Sitting tight, enjoying the show.

Paul
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News